Abstract
Purpose Circulating tumor cells (CTCs) have a tremendous potential for diagnosis and treatment of breast cancer patients. Here, we performed a unique analysis of all atypical circulating cells isolated with a filtration-based technology from metastatic breast cancer (mBC) patients.
Patients and methods The PERMED-01 study enrolled patients with mBC, refractory to systemic therapy, and with an accessible lesion to biopsy. We analyzed atypical circulating cells isolated from patients’ blood at the time of inclusion using Screencell® Cyto device. For 23 out of 91 analyzed patients, this was completed by advanced immunofluorescence staining of atypical circulating cells. Subsets cut-offs were established using a two-component Gaussian finite Mixture Model, and evaluated for correlation with clinico-pathological data, including progression-free survival (PFS) and overall survival (OS).
Results Three subsets of atypical circulating cells, absent from controls (n=7), were observed in cancer patients (n=91): isolated (iCTCs), Clusters (CTM), and Giant CTCs (gCTCs). CTCs’ median number was 8.33 per mL. Co-expression of stem and drug resistance markers was associated with intermediate epithelial to mesenchymal transition phenotype in CTM and gCTCs, but not in iCTCs. Presence of gCTC was associated with shorter PFS and OS. Concerning PFS, assigning an immunofluorescence-based Epithelial to Mesenchymal status improved their prognostic value.
Conclusion This study brings to light the diversity of CTCs in mBC patients and their specific molecular profiles regarding epithelial to mesenchymal transition, stemness and drug resistance status. It also highlights the involvement of an atypical circulating cell subset, the gCTCs, as a prognostic factor for PFS and OS.
Competing Interest Statement
AG received non-financial support from Astra Zeneca, Novartis, Pfizer, Roche.
Clinical Trial
NCT02342158
Funding Statement
This work has been supported by Inserm, Institut Paoli-Calmettes (SIRIC INCa-DGOS-Inserm 6038), and grants from the Ligue Nationale Contre Le Cancer (EL2016.LNCC/DaB, EL2019.LNCC/FB), Association Ruban Rose, and Foundation Groupe EDF. AL was supported by the fellowship DOC4 from the Fondation ARC (DOC20180507420). AA was supported by a postdoctoral fellowship from the Fondation ARC (PDF20180507565) and the Fondation de France (00107936). Conflict of Interest: AG received non-financial support from Astra Zeneca, Novartis, Pfizer, Roche.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
National ethics committee (CPP Sud-Mediterranee) registered as identifier NCT02342158 at the ClinicalTrials.gov platform
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest: AG received non-financial support from Astra Zeneca, Novartis, Pfizer, Roche
Funding support: This work has been supported by Inserm, Institut Paoli-Calmettes (SIRIC INCa-DGOS-Inserm 6038), and grants from the Ligue Nationale Contre Le Cancer (EL2016.LNCC/DaB, EL2019.LNCC/FB), Association Ruban Rose, and Foundation Groupe EDF. AL was supported by the fellowship DOC4 from the Fondation ARC (n°DOC20180507420). AA was supported by a postdoctoral fellowship from the Fondation ARC (n°PDF20180507565) and the Fondation de France (n°00107936).
Data Availability
Data will be available on request
Abbreviations
- mBC
- metastatic breast cancer
- CTCs
- Circulating Tumor Cells
- iCTCs
- isolated Circulating Tumor Cells
- gCTC
- giant Circulating Tumor Cells
- EM status
- Epithelial to Mesenchymal status
- EMT
- Epithelial to Mesenchymal Transition
- PFS
- Progression free survival
- OS
- Overall survival
- CTM
- Circulating tumor microemboli
- TN
- Triple Negative
- TAM
- Tumor Associated Macrophage
- CAMLs
- Cancer-Associated Macrophage-Like cells
